Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
토요일, 8월 29

ROCHE HOLDING LTD S/ADR by Roche Holding Ltd

RHHBYOTCQX
Trade with Public
Trade with Public
$55.19
-1.20-2.13%
가까이에: Aug 28, 5:00 PM EST
$55.21
0.020.04%
시간외: 4:02 PM EST
개요뉴스목표가재무심리지분 현황비교

ROCHE HOLDING LTD S/ADR by Roche Holding Ltd Analyst Price Targets

Wall Street analyst price targets and consensus rating for ROCHE HOLDING LTD S/ADR by Roche Holding Ltd (RHHBY).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Hold
Consensus RatingMarket Perform# Analysts1Avg. Consensus PT$40Upside to Avg. PT-27.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 12, 2023TD CowenSteve ScalaPT CutMarket Perform$45→$40

Analyst Ratings News

Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says

Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.
Vandana Singh

Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside

Genmab shared Phase 3 trial results for epcoritamab in lymphoma, missing overall survival but improving disease control, as analyst weighs approval risks and future trial data.
Vandana Singh

Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy

HC Wainwright upgrades Shattuck Labs on confidence in SL-325, a DR3 antibody aiming for stronger, durable IBD treatment amid TL1A concerns.
Vandana Singh

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile.
Vandana Singh

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.
Vandana Singh

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys

FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.
Vandana Singh

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved